1. Home
  2. BIRK vs COGT Comparison

BIRK vs COGT Comparison

Compare BIRK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$42.39

Market Cap

7.9B

Sector

N/A

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$38.89

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
COGT
Founded
1774
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
6.5B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
BIRK
COGT
Price
$42.39
$38.89
Analyst Decision
Strong Buy
Buy
Analyst Count
14
15
Target Price
$62.69
$33.50
AVG Volume (30 Days)
2.5M
1.4M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,871,000.00
Revenue This Year
$13.71
N/A
Revenue Next Year
$13.88
$506.58
P/E Ratio
$17.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.45
$3.72
52 Week High
$57.39
$43.73

Technical Indicators

Market Signals
Indicator
BIRK
COGT
Relative Strength Index (RSI) 59.62 54.34
Support Level $40.55 $36.52
Resistance Level $44.92 $41.31
Average True Range (ATR) 1.70 1.82
MACD 0.35 0.15
Stochastic Oscillator 95.63 66.97

Price Performance

Historical Comparison
BIRK
COGT

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: